Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Epidemiology of Cancer in Europe—What Are the Trends?

December 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

"There is both good and bad news about cancer in Europe,” said Dr. Peter Boyle of the European Institute of Oncology, Milan, Italy, at the 1997 European Cancer Conference. “One welcome development is the large decrease in the incidence of

"There is both good and bad news about cancer in Europe,” said Dr. Peter Boyle of the European Institute of Oncology, Milan, Italy, at the 1997 European Cancer Conference. “One welcome development is the large decrease in the incidence of stomach cancer in all parts of Europe, but unfortunately, the increasing age of the European Union (EU) population is linked with an increasing number of cases of cancer in total, with large increases in the incidence of Hodgkin’s lymphoma and malignant melanoma. In the next 15 years the proportion of people age 65 or over is likely to rise from 15% to 17%, a rise that will be matched by a similar fall in the 15 to 64 age group.”

“Levels of lung cancer and other smoking related cancers are high and still increasing, particularly in central and eastern Europe,” continued Dr. Boyle. “An epidemic of lung cancer is threatening women in southern Europe and this will pose a major problem for health services in coming decades.”

Dr. Boyle makes a strong call to action: “With our current knowledge, we could eliminate at least half of all cancers. We need to take practical steps to do this, rather than just discuss it.” 

Articles in this issue

Breast Cancer Treatment in Europe
The Sidney Kimmel Foundation for Cancer Research Seeks 1998 Scholar Applicants
New Study Shows Processed Tomato Products Are a Better Source of Lycopene Than Fresh Tomatoes
New Endocrine Treatments for Prostate Cancer
FDA Grant Given to Continue Studies of Aminopterin
American Association for Cancer Research 1998 Research Fellowships
Breast Cancer: The Importance of Local Control
Screening for Prostate Cancer-The European View
Testosterone Levels Early in Life May Determine Later Risk of Prostate Cancer
The Surgeon and Surgical Procedure as Prognostic Factors
Clinical Trial of New Agent to Overcome MDR Resistance in Multiple Myeloma Patients
Epidemiology of Cancer in Europe—What Are the Trends?
Surgical Outcomes in Gastric Cancer
Combined-Modality Therapy for Head and Neck Cancer
Study Suggests Smoking Is Associated with Chromosome Loss
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content
Advertisement

A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.


The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

Related Content
Advertisement

A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.


The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.